RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

Daviddal, Organon should ideally want to now focus more on the rest of their pipeline. But when something like this happens, companies often do the exact opposite - they put all their available resources into saving their one big program (Asenapine), since they have so much riding on it. Then the rest of their pipeline suffers from lack of funds. CTIC comes to mind - they would have been better off just dumping Xyotax altogether when it ran into trouble, and concentrating on Pixantrone. Instead they continue to whip a dead horse at the expense of the rest of the pipeline.

Having to count on Organon to bail Cortex out of its current mess is not good, but then again we may not have that many other options.